spacer
home > > summer 2009 > feeling the beat
PUBLICATIONS


Feeling the Beat

BACKGROUND: AN INDUSTRY SHIFT

In 2005, the US and European regulators introduced a new set of guidelines (E14 guidance) that require a robust characterisation of cardiac safety for noncardiac drugs. Specifically, drug developers are now required to demonstrate that their compounds do not have a significant effect on QT interval – a surrogate marker for arrhythmia liability that is measured from the surface electrocardiogram (ECG). These new guidelines were developed in response to the post-market withdrawal of nine non-cardiac drugs for cardiac safety reasons, of which five were withdrawn specifically for contributing to druginduced arrhythmias. The studies performed to evaluate the effect of novel drugs on the QT interval have become known as thorough QT (TQT) studies.

Immediately after the introduction of the E14 guidelines, many drug developers elected to conduct the TQT studies early in the clinical development process, as had been envisioned by the regulators. However, having gained experience in these types of studies over the past three years, pharmaceutical sponsors have realised that this investment frequently leads to suboptimal returns. Specifically, the cost of a TQT study can range from $1.5 to $5 million, but the study only answers a single regulatory question (characterisation of the drug effect on the QT interval) and, for example, in drugs that have normal autonomic mediated QT changes, does not answer this question very well.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer

Alexandra (Sasha) Latypova is co-founder and Executive Vice President of iCardiac Technologies, Inc. Prior to this position, Sasha headed sales and business development at VirtualScopics, Inc. She had previously worked as a Manager in healthcare practice at Analysis Group, Inc, where she advised pharmaceutical clients on a wide range of issues concerning product development, and provided economic analyses for pharmaceutical litigation cases. Sasha holds an MBA from the Amos Tuck School at Dartmouth College.

J Mikael Totterman is Chairman and CEO of iCardiac Technologies, a venture-backed company from the University of Rochester Medical Center. Prior to joining iCardiac Technologies, Mikael was Executive Vice President and Chief Operating Officer of VirtualScopics, Inc. Earlier in his career, he served as one of three principles responsible for overseeing a $250 million venture capital fund. He has also held positions at The Boston Consulting Group as well as Gemini Consulting. Mikael received his Bachelors Degree in Engineering from Stanford University, where he was a David Starr Jordan Scholar, and his MBA from the Amos Tuck School at Dartmouth College.

spacer
Alexandra Latypova
spacer
spacer
spacer
J Mikael Totterman
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals

Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >>

White Papers

What Your Clinical Study Design Reveals About Your Clinical Packaging Needs

PCI Pharma Services

As the cost and complexities of drug development increase, so do the challenges of global clinical trials. Today’s sponsors must be able to manage and coordinate multiple resources, processes, and locations with speed and accuracy to design effective and efficient clinical trials. Securing a stable supply chain to deal with the uncertainties of clinical trials is critical. One misstep can have a profound impact not only on the cost and time of your trial but also on its overall success.
More info >>

 
Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement